NZ202714A - 5-diazacycloalkyl-imidazo(1,2-c)(1,3)benzodiazepine derivatives,a method for their preparation and pharmaceutical preparations - Google Patents
5-diazacycloalkyl-imidazo(1,2-c)(1,3)benzodiazepine derivatives,a method for their preparation and pharmaceutical preparationsInfo
- Publication number
- NZ202714A NZ202714A NZ202714A NZ20271482A NZ202714A NZ 202714 A NZ202714 A NZ 202714A NZ 202714 A NZ202714 A NZ 202714A NZ 20271482 A NZ20271482 A NZ 20271482A NZ 202714 A NZ202714 A NZ 202714A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- hydrogen
- lower alkyl
- methyl
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 136
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 60
- -1 cyano, carboxy Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 50
- 229940049706 benzodiazepine Drugs 0.000 claims description 46
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 229910052783 alkali metal Inorganic materials 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 150000001340 alkali metals Chemical class 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 241000700159 Rattus Species 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 230000000701 neuroleptic effect Effects 0.000 claims description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 239000012267 brine Substances 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000009615 deamination Effects 0.000 claims description 2
- 238000006481 deamination reaction Methods 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 239000000725 suspension Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000007858 starting material Substances 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000003610 charcoal Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- 239000011976 maleic acid Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
- KSKKEMJYPOUZKJ-UHFFFAOYSA-N 2-(1h-imidazol-2-ylmethyl)aniline Chemical compound NC1=CC=CC=C1CC1=NC=CN1 KSKKEMJYPOUZKJ-UHFFFAOYSA-N 0.000 description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 229960005141 piperazine Drugs 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- YPRFCQAWSNWRLM-UHFFFAOYSA-N 2-(2-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1CC#N YPRFCQAWSNWRLM-UHFFFAOYSA-N 0.000 description 2
- TZWZGUNFZZTVNS-UHFFFAOYSA-N 2-[(2-nitrophenyl)methyl]-1h-imidazole Chemical class [O-][N+](=O)C1=CC=CC=C1CC1=NC=CN1 TZWZGUNFZZTVNS-UHFFFAOYSA-N 0.000 description 2
- RSAXUEMHVKBRSZ-UHFFFAOYSA-N 2-hydroxyimino-3-(2-nitrophenyl)propanoic acid Chemical compound ON=C(C(O)=O)CC1=CC=CC=C1[N+]([O-])=O RSAXUEMHVKBRSZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- DORZKSLHDKCKEO-UHFFFAOYSA-N 5-methyl-2-[(2-nitrophenyl)methyl]-1h-imidazole Chemical compound CC1=CNC(CC=2C(=CC=CC=2)[N+]([O-])=O)=N1 DORZKSLHDKCKEO-UHFFFAOYSA-N 0.000 description 2
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- QJKSKQPXIVRXRG-UHFFFAOYSA-N ethyl 2-(2-nitrophenyl)ethanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CC1=CC=CC=C1[N+]([O-])=O QJKSKQPXIVRXRG-UHFFFAOYSA-N 0.000 description 2
- DBIXWFNTHUIXOL-UHFFFAOYSA-N ethyl 4-carbonochloridothioylpiperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(C(Cl)=S)CC1 DBIXWFNTHUIXOL-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XDSFEVFCNJALNV-BTJKTKAUSA-N 1h-1,2-benzodiazepine;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.N1N=CC=CC2=CC=CC=C12 XDSFEVFCNJALNV-BTJKTKAUSA-N 0.000 description 1
- FMMHUIFSJWVNAE-UHFFFAOYSA-N 1h-1,3-benzodiazepine Chemical compound N1C=NC=CC2=CC=CC=C12 FMMHUIFSJWVNAE-UHFFFAOYSA-N 0.000 description 1
- LLMNPCDIPYPKHC-UHFFFAOYSA-N 2-(4-chloro-2-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1CC#N LLMNPCDIPYPKHC-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WNLJDGMBHGOYHR-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-2-yl)methyl]aniline Chemical compound CC1=CNC(CC=2C(=CC=CC=2)N)=N1 WNLJDGMBHGOYHR-UHFFFAOYSA-N 0.000 description 1
- PLAZTCDQAHEYBI-UHFFFAOYSA-N 2-nitrotoluene Chemical compound CC1=CC=CC=C1[N+]([O-])=O PLAZTCDQAHEYBI-UHFFFAOYSA-N 0.000 description 1
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- QDWTXRWOKORYQH-UHFFFAOYSA-N 3-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(Br)=C1 QDWTXRWOKORYQH-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- CVNRARCXNKDWKI-UHFFFAOYSA-N ethyl 2-(4-methylphenyl)sulfonyloxyacetate Chemical compound CCOC(=O)COS(=O)(=O)C1=CC=C(C)C=C1 CVNRARCXNKDWKI-UHFFFAOYSA-N 0.000 description 1
- KQMFQUHTZHJASG-UHFFFAOYSA-N ethyl 4-[[2-(1h-imidazol-2-ylmethyl)phenyl]carbamothioyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=S)NC1=CC=CC=C1CC1=NC=CN1 KQMFQUHTZHJASG-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 125000004997 halocarbonyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DXIAVVDXRGUGHE-UHFFFAOYSA-N n-[5-chloro-2-(1h-imidazol-2-ylmethyl)phenyl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC1=CC(Cl)=CC=C1CC1=NC=CN1 DXIAVVDXRGUGHE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical class OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003858 primary carboxamides Chemical class 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £02714
202714
si
Priority Date(s): ../.?.% !k(
Complete Specification Filed: . £.
Class:
Publication Date: .., ^ ^
r .C. Journal, To:
Ikft if-''
v- *
Patents Form No. 5
NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION "IMIDAZOBENZODIAZEPINES"
WE, CIBA-GEIGY AG, a Swiss Corporation of Klybeckstrasse 141, 4002 Basle, Switzerland,
hereby declare the invention, for which we pray that a patent may be granted to us,and the method by which it is to be performed, to be particularly described in and by the following statement
(Foflowed by page I A.)
2027 1
m-
4-13694/CGC 961/+
IMIDAZOBENZODIAZEPINES
The invention concerns 5-diazacycloalkyl-imidazo[l,2-c][l,3]benzo-diazepines of formula I
VA
4>\/ V\ _R (I)
i ii i ii n J
Xy\-5s 2
- x>
n 2n wherein each of the symbols and R^ is hydrogen, lower alkyl, lower 5 alkanoyl, halogen, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, sulfamoyl, mono- or di-lower alkyl-(carbamoyl or sulfamoyl);
is lower alkylene separating both nitrogen atoms by 2 or 3 carbon atoms; R^ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, aryl lower alkyl, lower alkoxycarbonyl, phenyl lower 10 alkoxycarbonyl or (hydroxy, lower alkanoyloxy, aryloxy or lower alkoxy) lower alkyl having at least two carbon atoms; R^ and R^ independently represent hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, trifluoromethyl, hydroxy, lower alkanoyloxy,
sulfamoyl, mono- or di-lower alkylsulfamoyl; and R, and R represent b /
hydrogen or lower alkyl; the N-oxides, lower alkyl quaternary derivatives, and salts, especially pharmaceutically acceptable salts thereof, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application.
The term "lower" referred to above and hereinafter in connection with 20 organic radicals or compounds respectively defines^e.gT")such alkyl, alkenyl und alkynyl radicals with up to and including 7, preferably
3
2027
up and including 4 and advantageously one or two carbon atoms.
Halogen is preferably fluoro or chloro, but may also be bromo or iodo.
A lower alkyl group or such present in said alkoxy, alkylthio or other alkylated groups, is above all methyl, but also ethyl, n- or i-(propyl, butyl, pentyl, hexyl or heptyl), e.g. 2-methylpropyl or 3-methylbutyl, lower alkenyl is preferably allyl and lower alkynyl is preferably propargyl.
Aryl lower alkyl is preferably benzyl, 1-, 2- or 3-phenylpropyl, 1- or 2-phenylethyl, said radicals being optionally substituted on the phenyl ring preferably by e.g. halogen, lower alkoxy or lower alkyl.
A lower alkoxy group preferably contains 1 to 4 carbon atoms and represents for example ethoxy, propoxy, isopropoxy or advantageously methoxy.
A lower alkylthio group preferably contains 1 to 4 carbon atoms and represents for example ethylthio, propylthio or advantageously methylthio.
The term "acyl" represents for example lower alkanoyl, lower alkoxy carbonyl, carbamoyl, sulfamoyl, mono- or di-lower alkyl (carbamoyl or sulfamoyl), halosulfonyl, phenyl lower alkoxycarbonyl and the like.
Lower alkanoyl is preferably acetyl or propionyl. Lower alkanoyloxy is preferably acetyloxy or propionyloxy.
202714
A lower alkoxycarbonyl, mono- or di-lower alkyl (carbamoyl or sulfamoyl) group is preferably methoxycarbonyl or ethoxycarbonyl; mono- or dimethyl(carbamoyl or sulfamoyl).
A phenyl lower alkoxycarbonyl group represents preferably 5 phenylmethoxycarbonyl or phenylethoxycarbonyl.
A lower alkylene group CnH2n i-s especially ethylene; but also 1,2-or 1,3-propylene, 1,2-, 1,3- or 2,3-butylene; thus forming with both adjacent nitrogen atoms a piperazinyl or homopiperazinyl moiety.
A lower hydroxyalkyl group is preferably 2-hydroxy-(ethyl or propyl), 10 3-hydroxy-(propyl or butyl) or 4-hydroxybutyl.
A lower alkanoyloxy lower alkyl group represents preferably lower alkanoyloxy (ethyl, propyl or butyl), e.g. 2-acetyloxy- or 2-propion-yloxy (ethyl, propyl or butyl), 3-acetyloxy- or 3-propionyloxy-(propyl or butyl), 4-acetyloxy- or 4-propionyloxybutyl and the like.,
A lower alkyloxy lower alkyl group represents preferably lower alkyloxy-(ethyl, propyl or butyl), e.g. 2-methoxy- or ethoxy-(ethyl, propyl or butyl), 3-methoxy- or 3-ethoxy-(propyl or butyl), 4-methoxy- or 4-ethoxybutyl and the like.
An aryloxy lower alkyl group represents preferably phenyloxy-20 (ethyl, propyl or butyl), said radicals being optionally substituted on the phenyl ring preferably by e.g. halogen, lower alkoxy or lower alkyl.
Lower alkyl quaternary salts of compounds of formula I are preferably, e.g. methyl, ethyl or propyl quaternary salts derived from 25 reactive esters of lower alkanols having preferably from 1 to 4
carbon atoms, e.g. methanol, ethanol or propanol. The anions of said quaternary salts are preferably those corresponding to pharma-
2027
ceutically acceptable acids such as halide, e.g. bromide or iodide; sulfate; or lower alkylsulfonate, e.g. methylsulfonate.
Although N-oxides or lower alkyl quaternary salts of compounds of formula I may represent such functionalized at one or more of any 5 of the depicted ring nitrogen atoms in formula I, said N-oxides,
lower alkyl quaternary salts of the compounds of formula I are preferably derived from those wherein is lower alkyl, aryl lower alkyl, or (hydroxy, lower alkanoyloxy, aryloxy or lower alkoxy)
lower alkyl having at least 2 carbon atoms in the lower alkyl group 10 and wherein only the nitrogen atom bearing said R^ substituent is thus functionalized.
Said compounds of Formula I form acid addition salts, which are preferably such of pharmaceutically acceptable inorganic or organic acids, such as strong mineral acids, for example hydrohalic, e.g. 15 hydrochloric or hydrobromic acid; sulfuric, phosphoric or nitric acid; aliphatic or aromatic carboxylic or sulfonic acids, e.g.
formic, acetic, propionic, succinic, glycolic, lactic, malic,
tartaric, citric, maleic, fumaric, hydroxymaleic, pyruvic, phenyl-acetic, benzoic, 4-aminobenzoic, anthranilic, 4-hydroxybenzoic, 20 salicylic, 4-aminosalicylic, pamoic, nicotinic; methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylenesulfonic, halogeno benzenesulfonic, p-toluenesulfonic, naphthalenesulfonic, sulfanilic or cyclohexylsulfamic acid; or ascorbic acid.
Compounds of formula I with R^ and/or R^ being carboxy also form salts 25 with bases,-preferably with such bases which yield pharmaceutically acceptable salts, for example, ammonium salts, mono, di- or tri-lower alkyl amines, lower alkylene amines, morpholine, piperazine, piperidine, or lower alkyl derivatives of said cyclic bases, alkali or alkaline earth metal salts.
2027
The compounds of the invention exhibit valuable pharmacological properties, psychoactive, e.g. neuroleptic, as well as antiallergic, e.g. antihistaminic effects. Such are demonstrable in animal tests using advantageously mammals, e.g. mice, rats, guinea pigs or monkeys, 5 as test objects. Said compounds can be applied to them enterally or parenterally, advantageously orally, or subcutaneously, intravenously or intraperitoneally, for example, within gelatin capsules or in the form of starchy suspensions or aqueous solutions respectively.
The applied dosage may range between about 0.1 and 100 mg/kg/day,
preferably between about 0.5 and 50 mg/kg/day, advantageously between about 1 and 30 mg/kg/day.
Said neuroleptic properties can be demonstrated in adult rats or squirrel monkeys, which were trained to press a lever to avoid the 15 onset of an electric foot shock. Each lever press postpones the shock for 30 seconds. Whenever the animal fails to press the lever once within said period, brief (0.5 sec.) shocks are delivered at 15 second intervals until the animal again presses the lever.
Under control conditions the animals press the lever at a moderately 20 steady rate and seldom receive more than five or six shocks during a 25-minute (rats) and up to 4-hour experimental session. Said compounds are administered to the animals 30, 90, 210 minutes prior to the experimental session and block the learned conditioned avoidance behavior, manifested by a decrease in avoidance responding 25 with a marked increase in shocks taken by the animal. Both the avoidance responses and failures (shocks received) are recorded separately for evaluation.
Finally, said antihistaminic properties can be shown in vitro, e.g., according to Chasin et al., J. Neurochem. 22^, 1031 (1974). Vesicles
from a cell free preparation of guinea pig cerebal cortex are
3 . 3
premcubated with H-adenine to form endogenous H-adenosine
2027
triphosphate. The vesicles are then incubated with 50 micromolar
3
histamine to activate H-cyclic adenosine monophosphate synthesis in the absence or presence of the test compound at a concentration between 0.01 and 100 micromolar. When said compound is active, it 5 inhibits the histamine activation of adenylate cyclase. The represents the concentration at which histamine activation is inhibited by 50%.
Accordingly, the compounds of the invention are useful neuroleptic and antihistaminic agents, for example, in the treatment or 10 management of psychotic manifestations, e.g., aggression, agitation, schizophrenia, and/or allergic conditions in mammals, including man. They are also useful intermediates in the preparation of other valuable products, especially of pharmacologically active compositions.
Preferred embodiments of this invention relate to compounds of formula I wherein each of and R^ is hydrogen, lower alkyl, cyano, carboxy, lower alkoxycarbonyl or carbamoyl; n represents the integer 2 to 4; R^ is hydrogen, lower alkyl, lower alkoxycarbonyl, or hydroxy lower alkyl of 2 to 4 carbon atoms; R^ represents hydrogen, lower 20 alkyl, lower alkoxy, lower alkylthio, halogen or trifluoromethyl; R,. represents hydrogen; and R^ and R^ represent hydrogen or lower alkyl; the N-oxides; lower alkyl quaternary salts; or salts, especially pharmaceutically acceptable salts thereof.
Highly preferred are compounds of formula I wherein each of R^ and 25 R2 is hydrogen, methyl, ethyl, cyano, carboxy, alkoxycarbonyl of 1 to 3 carbon atoms in the alkoxy portion or carbamoyl; n represents the integer 2 or 3; R^ is hydrogen, alkyl of 1 to 3 carbon atoms, alkoxycarbonyl of 1 to 3 carbon atoms in the alkoxy portion, hydroxyethyl or hydroxypropyl; R^ represents hydrogen, methyl, 30 methoxy, methylthio, chloro or trifluoromethyl; R,. represents hydrogen; R, and R. represent hydrogen or methyl; the N-oxides; methyl 0 /
2027
quaternary salts; and salts, especially pharmaceutically acceptable salts thereof.
Especially useful are compounds of formula II
y\yCH2\_A._R.
Li.*1 (ii)
R
/ ^ / \. 5/ "2
• n=»
4 V
\ <'~K3
n 2n
wherein R^ and R^ independently represent hydrogen or lower alkyl;
R^ represents hydrogen, lower alkyl or hydroxy lower alkyl wherein the hydroxy group is separated from the nitrogen atom by at least
2 carbon atoms; represents hydrogen, lower alkyl, lower alkoxy,
lower alkylthio, halogen or trifluoromethyl; C H represents n zn
ethylene or propylene; the N-oxides; and salts, especially pharmaceutically acceptable salts thereof.
Of particular interest are compounds of formula II wherein R^ and R^
independently represent hydrogen or methyl; R^ represents hydrogen,
methyl, ethyl, propyl, 2-hydroxyethyl or 3-hydroxypropyl; R^ is
hydrogen, methyl, methoxy, fluoro,chloro or trifluormethyl; C H
n 2n represents ethylene or propylene; the N-oxides and salts, especially pharmaceutically acceptable salts thereof.
Further preferred are compounds of formula II wherein R^ and R^ independently represent hydrogen or methyl; R^ represents hydrogen, 20 methyl, ethyl, propyl or 2-hydroxyethyl; R^ is hydrogen, methyl,
fluoro, chloro or trifluoromethyl and C H 'is ethylene, and salts, especially pharmaceutically acceptable salts thereof.
2027
Indicative of the antipsychotic utility of the compounds of this invention, e.g., the compound of example 1, namely 5-(4-methyl-l-piperazinyl)-HH-imidazo[l,2-c] [1,3]benzodiazepine disrupts avoidance behavior, e.g. decreases avoidance responses in rats and 5 monkeys at an oral dose of 30 mg/kg or lower.
Illustrative of the antihistaminic activity, 5-(4-methyl-l- s piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine, the compound of example 1, inhibits histamine activation of adenylate cyclase,
with an of about 1 x 10 %,
Furthermore, 5-(4-methyl-l-piperazinyl)-llH-imidazo[l,2-c][1,3]— benzodiazepine, the compound of example 1, an illustrative example of this invention, is essentially free of extrapyramidal side effects, e.g. dyskinesias and dystonias in the monkey (dyskinetic movements and dystonic postures) and shows only minimal a-adrenergic 15 blocking activity in vitro.
The compounds of the invention are prepared according to methods known per se, advantageously by a) condensing a compound of formula III
wherein X is a group detachable together with hydrogen or an alkali metal and the remaining symbols have meaning as defined for formula I; with a compound of formula IV
(III)
2027 14
HN,
/
V
-R„
n 2n
(IV)
or an alkali metal derivative thereof wherein has meaning as defined for formula I; and, if desired, converting any resulting compound of formula I into another compound of the invention.
A group detachable together with hydrogen or an alkali metal atom is for example in particular a free or preferably etherified mercapto group, also an optionally functionally modified reactive hydroxy group, the cyanato, thiocyanato or the nitroamino group. An etherified mercapto group is especially a mercapto group etherified 10 by an optionally substituted hydrocarbon, particularly one of aliphatic character. It is especially lower alkylthio, for example methylthio, ethylthio or butylthio, or phenyl-lower-alkylthio, for example phenylthio or benzylthio. An optionally functionally modified reactive hydroxy group is a free hydroxy group or, for 15 example, a corresponding esterified hydroxy group. This is for example halogen, such as chlorine or bromine, or lower alkylsulfonyl-oxy, for example methanesulfonyloxy. An etherified hydroxy group is for example a lower alkoxy group, such as methoxy or ethoxy.
Said condensation is advantageously carried out with an excess of 20 the compound IV, or with equivalent amounts of said metal derivatives prepared in situ therefrom, preferably when X in formula III is halogeno, lower alkylthio or thiocyanato, advantageously and depending on the nature of said X, at temperatures between about 0° and 150°, and preferably in an appropriate solvent e.g. a lower 25 alkanol such as amyl alcohol, dimethylformamide, hexamethylphosphor-amide or toluene. Said condensation of a compound of formula III with a compound of formula IV may also be carried out in the presence of an acid, e.g., a hydrohalic acid such as hydrochloric acid.
2 027
The novel llH-imidazo[l,2-c][l,3]benzodiazepine starting materials of formula III are prepared according to ring closure methods known per se. Advantageously by condensing compounds of formula V
v6\ 7*7
R
%\ / \ A A
1 - i_'j <v)
E5
\h„ h
wherein R^, R^, have meaning as previously defined for formula I with reactive carbonic acid derivatives such as phosgene, thiophosgene, l,l'-carbonyldiimidazole, cyanogen bromide or phenyl chloroformate.
Compounds of formula III wherein X is hydroxy can be converted to 10 compounds wherein X is sulfhydryl by conventional sulfurating agents, such as phorphorus pentasulfide.
These compounds of formula III can be further derivatized to compounds of formula III above wherein X has the meaning given above, analogous to the procedures illustrated by the examples herein.
Starting materials of formula V are preferably prepared by reduction of the corresponding variously substituted 2-(o-nitrobenzyl)imidazoles, which are in turn preferably prepared from the correspondingly substituted o-nitrobenzylnitriles and 2-aminoacetals (or ketals), e.g. aminoacetaldehyde dimethyl acetal, by known methods illu-
strated in the examples herein.
A further process for the preparation of the compounds of general formula I consists in
2027
ii -
b) cyclizing a compound of formula VI
hn"—*-r,
(VI)
nnh—c-t/ \ R5 II c h;
I II 2
• • • — •
'-r,
3
z wherein Z is oxygen, sulfur, or NH, and the other symbols have the above-given meaning, under dehydrating, dehydrosulfurating or 5 deamination conditions, and if desired converting any resulting compound into another compound of the invention.
Said cyclization is preferably carried out at temperatures between 0° and 120°, with a reagent such as a phosphorus halide, for example, phosphorus pentachloride and/or phosphorus oxychloride or a 10 cyanogen halide, with or without a crown ether catalysator, for example 8-crown-6-ether, with or without basic catalysts such as triethylamine or potassium carbonate, advantageously in an inert solvent, such as acetonitrile or toluene.
The starting materials of Formula VI ean be 15 obtained according to methods known per se. For example they can be prepared from percursors of Formula III or tautomers thereof, wherein X is hydroxy, thio or amino by condensing them with compounds of Formula IV in the presence or absence of other bases, e.g. those listed above, preferably in an inert solvent, such as methylene 20 chloride or toluene at temperatures between 0° and 150° advantageously between 10° and 50°. The ring opening reaction is preferably carried out at low temperature to minimize side reactions when R^ and R^ represent reactive functional groups.
Alternately, starting materials of formula VI, wherein R^ is lower 25 alkanoyl, lower alkoxycarbonyl or phenyl lower alkoxycarbonyl, are prepared by condensing a compound of formula V above with a compound
2027
12
of formula VII
H>
R.
'3
(VII)
C
'n 2n wherein Y' represents halocarbonyl, halothiocarbonyl or cyano, preferably in an inert solvent, at temperatures between about 0° and
150°, with or without basic catalysts such as triethylamine or potassium carbonate.
Starting materials of formula VII are preferably obtained by reacting compounds of formula IV wherein R^ has the meaning given for formula VII, or advantageously e.g. the N-trimethylsilyl 10 derivative thereof, with phosgene, thiophosgene or cyanogen bromide in an inert solvent such as ethyl ether, methylene chloride or dimethoxyethane at temperatures of about -70° to +50° with or without basic catalysts such as triethylamine or potassium carbonate.
The compounds of the invention so obtained can be converted into 15 other compounds of Formula I according to known methods. Thus, for example, those with R^ being hydrogen or alkali metal, e.g., sodium or lithium salts thereof, can be reacted with substituted or un-substituted oxiranes, such as ethylene oxide, or reactive esters of unsubstituted or correspondingly substituted aliphatic or arali-20 phatic alcohols such as methanol, ethanol, methoxyethanol, phenoxy-ethanol, allyl alcohol, propargyl alcohol, e.g. such esterified by a strong inorganic or organic acid, above all hydrohalic acids, e.g. hydrochloric, hydrobromic or hydriodic acid; sulfuric or an aromatic sulfonic acid, e.g. p-toluene or m-bromobenzene sulfonic acid, in 25 order to obtain the corresponding N-substituted compounds or quaternaries respectively, depending on the molar amount of the alkylating agent employed. Intermediates of formula I wherein R^ is
202714
alkali metal or alkali metal derivatives of compounds of formula IV are obtained by metallation with reactive organometallic agents such as lithium diisopropylamide, with alkali metal alkoxides such as sodium methoxide, or alkali metal hydrides such as sodium or potassium hydride.
Unsaturated compounds, such as those with being lower alkenyl, lower alkynyl may be hydrogenated with catalytically activated hydrogen to obtain compounds wherein R^ is the corresponding lower alkyl. Conversely, resulting N-alkylated compounds can be converted into N-unsubstituted compounds, e.g. by catalytic hydrogenolysis of 10 N-benzyl compounds, or reaction of N-lower alkyl derivatives with lower alkyl haloformates, e.g. ethyl chloroformate, to yield N-acyl derivatives which, in turn, may be hydrolyzed to said unsubstituted compounds, those with = H, for example with aqueous bases,
such as alkali metal hydroxides, e.g. aqueous sodium hydroxide 15 solution.
Compounds of formula I wherein R^ is hydroxy lower alkyl can also be prepared by first reacting corresponding compounds of Formula I, wherein R^ represents hydrogen, with reactive derivatives of corresponding glycols, glycolic acids or dicarboxylic acids, such as 15 lower alkyl esters, halides or anhydrides thereof, or reactive esters of said glycols or glycolic acid derivatives, for example with hydrohalic or aromatic sulfonic acids, 1,2-dibromoethane or -propane, ethyl bromoacetate or -propionate, ethyl tosyloxyacetate; diethyl oxalate or malonate or ethyl oxalyl chloride. The inter-20 mediates so obtained are either hydrolyzed or reduced with simple or complex light metal hydrides such as lithium aluminium hydride, alone or with diborane to compounds of formula I wherein R^ is hydroxyalkyl.
Compounds of formula I wherein R^ is lower alkyl, e.g. methyl can be prepared by reacting the corresponding compounds of formula I wherein
->7 2027
represents hydrogen with lower alkyl or phenyl lower alkyl halo-formates, such as ethyl chloroformate, to obtain compounds of formula I wherein R^ is lower alkoxycarbonyl or lower phenylalkyloxy-carbonyl, and reducing said acyl derivatives with simple or complex light metal hydrides such as lithium aluminium hydride, sodium tri-t-butoxy or sodium bis-(2-methoxyethoxy) aluminium hydride.
N-acylated derivatives of formula I wherein R^ is lower alkanoyl can preferably be obtained from compounds of Formula I with R^ being hydrogen and corresponding reactive carboxylic acid derivatives, e„g., halides, simple or activated esters, such as alkyl or cyano-alkyl esters, anhydrides or isocyanates. These in turn can be reduced as above to the compounds of formula I wherein R^ is lower alkyl. Compounds of formula I wherein R^ is hydroxy lower alkyl may be acylated as above to the compounds wherein R^ is lower alkanoyloxy lower alkyl.
Compounds of Formula I with R^ and/or R^ being hydrogen, may be converted to the corresponding compounds with and/or R^ being halogen or acyl, e.g. by halogenation, preferably with chlorine in acetic acid or under Friedel-Crafts conditions by acylation with a trihaloacetyl halide or a halosulfonic acid optionally followed by treatment with an alkali metal lower alkoxide, hydroxide or amide. Any resulting carboxylic or sulfonic acid derivatives may then be hydrolyzed in known fashion, preferably under alkaline conditions and/or amidized with ammonia, mono- or di-lower alkyl-r amines; the resulting primary carboxamides may in turn be dehydrated to the corresponding nitriles according to conventional methods. Compounds of the formula I in which R^ and/or R^ represents carboxy, can be prepared, for example, by hydrolysis of compounds wherein R^ and/or R^ represents cyano, lower alkoxycarbonyl or carbamoyl.
2 027
Tertiary amines in which differs from hydrogen and is e.g. lower alkyl or aryl lower alkyl, can be converted into the N-oxides, for example with hydrogen peroxide or organic peracids, such as lower peralkanoic or perbenzoic acids, e.g. peracetic or m-chloroperbenzoic 5 acid, advantageously at temperatures at or below room temperature with the latter, or up to 100° with hydrogen peroxide in the presence of lower alkanoic acids, e.g. acetic acid. If only a mono N-oxide is desired, care should be taken in order to prevent further oxidation.
Finally, the compounds of the invention are either obtained in the free form, or as a salt thereof. Any resulting base can be converted into a corresponding acid addition salt, preferably with the use of acids which yield a pharmaceutically acceptable salt or with anion exchange preparation, or any resulting salt can be converted into 15 the corresponding free base, for example, with the use of a stronger base, such as a metal or ammonium hydroxide or a basic salt, e.g. an alkali metal hydroxide or carbonate, or a cation exchange preparation. Said acid addition salts are preferably such of pharmaceutically acceptable inorganic or organic acids described 20 previously.
Compounds of formula I with R^ and/or R^ being carboxy can be converted into the corresponding metal or ammonium salts by e.g. treatment with the alkaline or alkaline earth metal hydroxides or carbonates, ammonia or the amines listed previously.
These or other salts, for exmaple, the picrates, can also be used for purification of the bases obtained; the bases are converted into salts, the salts are separated and the bases are liberated from the salts.
2027 14
In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
In case mixtures of geometrical or optical isomers of the above compounds, e.g. I to VII are obtained, these can be separated into the single isomers by methods in themselves known, e.g. by fractional distillation, crystallization and/or chromatography. Racemic products can likewise be resolved into the antipodes, for example, by se-10 paration of diastereomeric salts thereof, e.g. by the fractional crystallization of the salts formed with d- or 1-tartaric acid.
The above-mentioned reactions are carried out according to standard methods, in the presence or absence of diluents, preferably such as are inert to the reagents and are solvents thereof, of catalysts, 15 condensing or said other agents respectively and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures, preferably at the boiling point of the solvents used, at atmospheric or superatmospheric pressure.
The invention further includes any variant of the present process, 20 in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or the process is discontinued at any stage thereof, or in which the starting materials are formed under the reaction conditions, or in which the reaction components are used in the form of their 25 salts or optically pure antipodes. Mainly those starting materials should be used in said reactions, that lead to the formation of those compounds, indicated above as being especially valuable, e.g. those of Formula II.
2027
The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with exci-pients suitable for either enteral or parenteral application.
Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose,
sucrose, mannitol, sorbitol, cellulose and/or glycine, b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol, for tablets also c) binders, e.g. 10 magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, if desired, d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures and/or e) absorbents, colorants, flavors and sweeteners. Injectable compo-15 sitions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic 20 pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient. A unit dosage for a 25 mammal of about 50 to 70 kg weight may contain between about 25 and 200 mg of the active ingredient.
The following Examples a) to e) are intended to illustrate some typical forms of application, but in no way do they represent the only embodiments thereof. Specific demonstrations are given in the 30 Examples.
2027
a) 100.0 g of active substance are mixed with 610.0 g of lactose and 442.0 g of potato starch; the mixture is then moistened with an alcoholic solution of 8 g of gelatine, and is granulated through a sieve. The granulate is dried, and 60.0 g of talcum, 10.0 g of 5 magneisum stearate and 20.0 g of colloidal silicon dioxide are mixed in; and the mixture is subsequently pressed to form 10,000 tablets, each weighing 125 mg and each containing 10 mg of active substance. The tablets can, if desired, be provided with grooves for a more precise adjustment of the dosage amount.
b) A granulate is prepared from 100.0 g of active substance, 379 g of lactose and the alcoholic solution of 6.0 g of gelatine; after drying, the granulate is mixed with 10.0 g of colloidal silicon dioxide, 40.0 g of talcum, 60.0 g of potato starch and 5.0 g of magnesium stearate} and the mixture is pressed out to form 10,000 15 dragee cores. These are subsequently coated with a concentrated syrup prepared from 533.5 g of crystallised saccharose, 20.0 g of shellac, 75.0 g of gum arabic, 250.0 g of talcum, 20.0 g of colloidal silicon dioxide and 1.5 g of colouring agent, and finally dried. The dragees obtained each weigh 150 mg and each contain 10 mg 20 of active substance.
c) 10.0 g of active substance and 1990 g of finely ground suppository foundation substance (for example cocoa butter) are thoroughly mixed and then melted. The melt is maintained homogeneous by stirring whilst 1000 2.0 g suppositories each containing 25 mg
of active substance are being poured.
d) To prepare a syrup having a content of active substance of 0.25%, there are dissolved in 3 litres of distilled water, 1.5 litres of glycerin, 42 g of p-hydroxybenzoic acid methyl ester, 18 g of p-hydroxybenzoic acid-n-propyl ester and, with slight warming,
2027
.0 g of active substance; to this solution are then added 4 litres of 70% sorbitol solution, 1000 g of crystallised saccharose, 350 g of glucose and an aroma substance, for example 250 g of "Orange Peel Soluble Fluid", Eli Lilly and Co., Indianapolis, or 5 g of 5 natural lemon aroma and 5 g of "half and half" essence, both from Haarmann and Reimer, Holzminden, Germany; the solution obtained is filtered, and the filtrate is subsequently made up with distilled water to 10 litres.
e) To prepare a drip solution containing 1.5% of active substance, 10 150.0 g of active substance and 30 g of sodium cyclamate are dissolved in a mixture of 4 litres of ethanol (96%) and 1 litre of propylene glycol. A mixture of 3.5 litres of 70% sorbitol solution and 1 litre of water is prepared separately and is then added to the above solution of active substance. An aroma substance, for example 15 5 g of cough-sweet aroma or 30 g of grapefruit essence, both from Haarmann and Reimer, Holzminden, Germany, is added; the whole is well mixed, filtered, and made up with distilled water to 10 litres.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Tempera-20 tures are given in degrees Centigrade, and all parts wherever given are parts by weight. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 and 100 mm Hg.
Example 1: Amyl alcohol (5100 ml) and 918.35 g (9.17 moles) of N-methyl-25 piperazine are charged into a 12 liter 3—necked reaction flask fitted with a Dean-Stark adapter. The solution is stirred under nitrogen atmosphere and 989 ml of 10N ethanolic hydrogen chloride solution are
2027
added rapidly. The reaction mixture is heated to reflux and the distillate is collected in the Dean-Stark adapter. When the temperature of the reaction mixture reaches 131° the Dean-Stark adapter is removed and an additional 918.35 g (9.17 moles) of N-methylpiperazine 5 followed by 1045.0 g (4.56 moles) of 5-methylthio-llH-imidazo[1,2-c]-[l,3]benzodiazepine are added. The mixture is heated at reflux under nitrogen atmosphere for 20 hours. Amyl alcohol is then removed under reduced pressure at a water bath temperature of 80°. The viscous residual oil is dissolved in 10,000 ml of dichloromethane, washed 10 with 3 x 4,000 ml of 4N sodium hydroxide and 6 x 4,000 ml of water. The dichloromethane solution is then extracted with 3 x 2,000 ml of 6N hydrochloric acid. The aqueous solution is back washed with 2 x 2,000 ml of dichloromethane, treated with 100 g of activated carbon and filtered. The clear filtrate is adjusted to pH 9-10 with 15 1,500 ml of ammonium hydroxide solution (29%). The oil which separates is extracted with 3 x 4,000 ml of dichloromethane, the extracts are dried over 1,000 g of sodium sulfate and the solvent removed at reduced pressure with a water bath temperature of 60°. An oil is obtained which rapidly solidifies and after drying further (5 mm 20 Hg/40°) yields crude product, m.p. 113-120°. The crude product is dissolved in 8,000 ml of hot (60-70°) isopropanol. The solution is decolorized with 200 g of activated carbon and filtered. To this solution is added a solution of 760.7 g (8.28 moles) of maleic acid in 2,500 ml of warm (30°) isopropanol and the maleate salt begins to 25 precipitate. The suspension is stirred overnight at ambient temperature to complete crystallization and the solid is collected by filtration. The product is washed with 3 x 500 ml of cold isopropanol and dried (0.5 mm/500). This is recrystallized from ethanol, the resulting product is washed first with ethanol and then 30 with ether and then dried to give 5-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][l,3]benzodiazepine monomaleate, m.p. 204-205° (decomposition).
2 027
A solution of 2,246 g of the above maleate salt in 9000 ml of water is treated with 100 g of activated carbon and filtered. The aqueous solution is adjusted to pH 9 with 1000 ml of 29% ammonium hydroxide and the free base separated as an oil. The oil is extracted with 5 3 x 2000 ml of dichloromethane, the extract is dried over sodium sulfate, filtered and the solvent is removed under reduced pressure at a water bath temperature of 40°. The solid obtained is recrystal-lized from 14,130 ml of heptane. The light yellow solid is collected and washed with 2 x 500 ml of heptane and dried (0.01 mm/500) to 10 give 5-(4-methyl-l-piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine m.p c 123-4°.
The starting material is prepared as follows: Absolute ethanol (24,000 ml) and 3,240 g (60.0 moles) of sodium methoxide are charged into a 70 litre reaction flask. The solution is stirred under 15 nitrogen while a solution of 8228.4 g (60.0 moles) of o-nitrotoluene and 8768.4 g (60.0 moles) of diethyl oxalate is added all at once. The resulting solution is heated at reflux for 25 minutes, cooled to 60° with an ice-bath and 18,000 ml of water are cautiously added. Heat is then applied and the mixture is held at the reflux 20 temperature for 1 hour. Most of the ethanol is then removed. The turbid,solution is cooled at 50° and a solution of 4,140 g (59.6 moles) of hydroxylamine hydrochloride in 6,000 ml of water is added all at once. The temperature is maintained at 50°, the pH is adjusted to 7.0 with 6,000 ml of 10 N sodium hydroxide solution 25 and the reaction mixture stirred overnight at ambient temperature. The suspension is cooled to 10° and the pH is adjusted to 1.0 with 6,000 ml of 12 N hydrochlorid acid. The stirring is continued overnight at 10° to complete the liberation of the free acid. The solid is collected, washed with 6 x 4,000 ml of water, air dried overnight and suspended in 20,000 ml of toluene. The suspension is stirred for 1 hour under nitrogen atmosphere. The product is collected,
washed with 4 x 2,000 ml of toluene followed by 4 x 2,000 ml of
2 027 14
petroleum ether arid dried (5 mm Hg/60°) to give 2-nitrophenylpyruvic acid oxime, m.p. 158-60° (decomposition).
Water (50,000 ml), 2,940 ml of glacial acetic acid and (22.22 moles) of 2-nitrophenylpyruvic acid oxime are charged into a 70 litre 5 reactor. The stirred suspension is heated over two hours under nitrogen atmosphere to 90° and this temperature is maintained for 2 hours. The dark solution is allowed to cool slowly and is stirred overnight at ambient temperature. The suspension is extracted with 5 x 4,000 ml of methylene chloride, washed with 3 x 3,000 ml of 10 water, dried over magneisum sulfate and filtered. The filtrate is treated with activated carbon, filtered and the solvent is removed under reduced pressure. The solid residue is recrystallized from 1,000 ml of isopropanol to give 2-nitrophenylacetonitrile, m.p. 82-84°.
Absolute ethanol (2,250 ml) and 1,500 g (9.25 moles) of o-nitro-
phenylacetonitrile are charged into a 22 liter flask. The suspension is cooled to 5-10° and hydrogen chloride is bubbled into the mixture for 2.5 hours. The reaction mixture is stirred at 10° under nitrogen atmosphere overnight. It is then diluted with 16,000 ml of ether 20 and stirred for 1 hour; the solid is collected by filtration, washed with 4 x 1,000 ml of ether, dried (5 mm Hg/40°), to give ethyl 2-(2-nitrophenyl)acetimidate hydrochloride, m.p. 122-123° (decomposition) .
Ethanol (2,200 ml) and 5,156 g (8.81 moles) of ethyl 2-(2-nitro-25 phenyl)acetimidate hydrochloride are charged into a 22 liter flask. The suspension is stirred under nitrogen at room temperature and 1022.9 g (9.73 moles) of aminoacetaldehyde dimethylacetal are added all at once. The mixture is stirred for 1 hour and 1,693 ml
27 1
of 12N hydrochloric acid are added all at once to cause a gentle exotherm reaction (to 40°). Heat is then applied and the temperature is maintained at 70-80° for 30 minutes. The solution is cooled to 20° (ice-water bath) and diluted with 2,700 ml of 10N sodium hydroxide 5 solution to precipitate the product. The suspension is stirred at 10° for 1 hour under nitrogen atmosphere, the solid collected by filtration and washed with 3 x 2,000 ml of water to give 2-(2-nitro-benzyl)-imidazole, m.p. 155-157°.
50% Aqueous ethanol (5,672 ml) and 2,890 g (14.22 moles) of 2-(2-10 nitrobenzyl)-imidazole are charged into a 22 liter flask. The suspension is stirred under nitrogen atmosphere and 2,400 g (42.97 moles) of iron powder (100 mesh) are added all at once. The mixture is then warmed to 70° and a solution of 1.7 ml of 12N hydrochloric acid in 8.3 ml absolute ethanol are added. A vigorous exotherm reaction 15 results and a strong reflux occurrs that persists for 1.5 hours.
When the exotherm reaction subsides, a mixture of 290 ml of 12N HC1 and 1400 ml of absolute ethanol are added over 30 minutes„ Heat is applied and the mixture is refluxed for 2 hours, diluted with 6,500 ml of absolute ethanol and adjusted to pH 8-9 with 700 ml of 10N sodium 20 hydroxide. The suspension is stirred for 1 hour and filtered. The cake is washed with 1,000 ml of absolute ethanol, the filtrates are combined and the solvent is removed. The remaining solid is then suspended in 10,000 ml of water, stirred under nitrogen atmosphere for two hours, collected, washed with 2,000 ml of water, and dried to 25 yield 2-(2-aminobenzyl)-imidazole, m.p. 153-155°.
Dichloromethane (42,000 ml) and 5,120 g (50.65 moles) of triethylamine are charged into a 70 litre flask. The solution is stirred under nitrogen atmosphere and 4,370 g (25.23 moles) of 2-(2-aminobenzyl)-imidazole are added. The suspension is cooled to 0-5° and 3,421 g 30 (29.75 moles) of 85% thiophosgene in carbon tetrachloride are added over 3 hours, during which time the reaction temperature rises slowly
2027
to 15°. The suspension is then stirred at 10° for 4 hours and at ambient temperature overnight. The precipitated product is collected, washed with 2 x 3000 ml of dichloromethane and 5 x 4000 ml of water, and dried (5 mm Hg/60°) to give llH-imidazo[l,2-c][1,3]benzodiazepine-5 5(6H)-thione, m.p. 182-183°.
Absolute ethanol (20,000 ml) is charged into a 70 litre flask and stirred under nitrogen atmosphere; 517,62 g (9.58 moles) of sodium methoxide are added. After stirring for 30 minutes there is complete solution and 2,063 g (9.58 moles) of llH-imidazo[1,2-c][1,3]benzo-10 diazepine-5(6H)-thione are added. There is complete solution after stirring at room temperature for 1 hour. The solution is then cooled to 1°, and 1.360 g (9.58 moles) of methyl iodide are added over 30 minutes. The reaction mixture is stirred at 5° for 4 hours and at ambient temperature overnight. The turbid solution is then cooled 15 to 5° and diluted with 50,000 ml of water. The resulting suspension is stirred for 4 hours at 5°. The solid is collected, and dried (5 mm Hg/60°) to give 5-methylthio-llH-imidazo[l,2-c][l,3]benzodiazepine, m.p. 87-88°.
Similarly prepared from 4-chloro-2-nitrophenyl-acetonitrile is 20 8-chloro-llH-imidazo[l,2-c][l,3]benzodiazepine-5(6H)-thione, m.p. 200-201° and 8-chloro-5-methylthio-llH-imidazo[l,2-c][l,3]benzo-diazepine hydrochloride, m.p. 255-257°.
The following starting materials are similarly prepared from the correspondingly substituted 2-nitrophenylacetonitriles: 25 a) 8-methyl-5-methylthio-llH-imidazo[1,2-c][1,3]-benzodiazepine;
b) 8-fluoro-5-methylthio-llH-imidazo[1,2-c][1,3]-benzodiazepine;
c) 8-methoxy-5-methylthio-llH-imidazo[1,2-c][1,3]benzodiazepine.
2 027
Example 2: To a suspension of 2.46 g of l-[2-(2-imidazolylmethyl)-phenylcarbamoyl]-4-methylhomopiperazine in 19.4 ml of phosphorus oxychloride is added at once 1.66 g of phosphorous pentachloride and the mixture is stirred at room temperature for 4 hours. The 5 mixture is evaporated to dryness, the residue is suspended in 45.2 ml of methylene chloride, the suspension is cooled to 0° and 21.4 ml of triethylamine are added dropwise with stirring over a period of 15 minutes. The mixture is allowed to warm up to room temperature, stirred for 1.5 hours and poured into 10% aqueous potassium carbonate. 10 The methylene chloride layer is separated, the aqueous layer is washed with methylene chloride,and the combined methylene chloride extracts are dried over magnesium sulfate, decolorized with charcoal and evaporated to dryness. The residue is purified by column chromatography with 50 g of silica gel, using methylene chloride-methanol-15 conc. ammonium hydroxide (300:50:1) as eluent to give 5-(4-methyl-l-homopiperazinyl)-llH-imidazo[1,2-c][l,3]benzodiazepine as an oil.
This free base is dissolved in acetone and treated with maleic acid to give 5-(4-methyl-l-homopiperazinyl)-llH-imidazo[l,2-c][l,3]benzo-diazepine monomaleate, m.p. 160-163°.
5-(4-Methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]-benzodiazepine monomaleate of example 1 is similarly prepared from l-[2-(2-imidazolyl-methyl)phenylcarbamoyl]-4-methy1-piperaz ine.
The starting materials are prepared as follows:
A solution of 32.4 g of phenyl chloroformate in 100 ml of aceto-25 nitrile is added dropwise under nitrogen while stirring to a mixture of 34.6 g of 2-(2-aminobenzyl)-imidazole and 71 g of triethylamine in 600 ml of acetonitrile at room temperature. After addition is complete, the reaction mixture is heated under reflux for 12 hours, and allowed to cool to room temperature. Water (150 ml) is added, 30 the mixture is stirred at room temperature for 0.5 hour and cooled to 5°. The resulting precipitate is filtered off, washed first twice with 50 ml of water, then 3 times with 33 ml of cold acetone and
202714
dried to give llH-imidazo[1,2-c][1,3]benzodiazepin-5(6H)-one, m.p. 255-257°.
Alternately, 0.75 g of 1,1'-carbonyldiimidazole is added at once to a suspension of 0.79 g of 2-(2-aminobenzyl)-imidazole in 38 ml of 5 methylene chloride and the mixture is stirred at room temperature overnight. The resulting precipitate is collected and recrystallized from methylene chloride to give the crude llH-imidazo[1,2-c][1,3]-benzodiazepin-5(6H)-one, m.p. 238-240°.
In analogous fashion, or by using phosgene as the reagent for 10 cyclization, the following intermediates are obtained:
a) 2,3-dimethy1-llK-imidazo[1,2-c][1,3]benzodiazepin-5-(6H)-one;
b) 8-chloro-llH-imidazo[1,2-c][l,3]benzodiazepin-5(6H)-one;
c) 8-methyl-llH-imidazo[l,2-c][l,3]benzodiazepin-5-(6H)-one;
d) 8-methoxy-llH-imidazo[1,2-c][l,3]benzodiazepine-5-(6H)-one.
To a suspension of 0.76 g of llH-imidazo[1,2-c][l,3]benzodiazepin-5-(6H)-one in 9 ml of methylene chloride is added at once 0.41 g of N-methylhomopiperazine and the mixture is stirred at room temperature for 24 hours. The reaction mixture is filtered and the filtrate is evaporated to dryness. Recrystallization of the 20 residue from methylene chloride-ether gives l-[2-(2-imidazolyl-
methyl)-phenylcarbamoyl]-4-methylhomopiperazine, melting at 139-143°.
Similarly prepared from N-methylpiperazine is l-[2-(2-imidazolyl-methyl)-phenylcarbamoyl]-4-methylpiperazine, m.p. 172-174°.
The following compounds are prepared according to the above proce-25 dures:
a) 1-[2-(4,5-dimethy1-2-imidazolylmethyl)-phenylcarbamoyl]-4-methyl-piperazine; and b) 1—[2—(2-imidazolylmethyl)-5-chlorophenylcarbamoyl]-4-methyl-piperazine.
2027
Example 3: A solution of 2.4 g of 5-cyanomercapto-llH-imidazo[1,2-c]-[1,3]benzodiazepine in 5 ml of hexamethylphosphoramide is cooled to -5° and 2.1 g of N-methylpiperazine is added dropwise with efficient mechanical stirring and under nitrogen, over a period of 5 minutes.
Stirring is continued for 10 minutes at -5° and another 10 minutes after removal of the cooling bath. The mixture is diluted with 100 ml of ethyl acetate and the solution washed twice with brine, dried over magnesium sulfate, and evaporated to dryness. To the residue, a solution of 1.2 g of maleic acid in 3 ml acetone is added and the 10 mixture is diluted with ether. The crude product crystallized, m.p.
183-186°, and is recrystallized to give the 5-(4-methyl-l-piperazinyl)~ HH-imidazo[l,2-c][l,3]benzodiazepine monomaleate of example 1. It melts at 204-205° (decomposition).
The starting material is prepared as follows:
Sodium hydride (50% in mineral oil, 1.44 g,) is washed with dry ether and suspended in 100 ml of dry tetrahydrofuran; 6.45 g of HH-imidazo[l,2-c][l,3] benzodiazepine-5(6H)-thione is added in portions to the suspension of sodium hydride, with stirring and under nitrogen, over a period of 2 minutes. The mixture is stirred at 20 room temperature for 1.5 hours. The white suspension, which was formed by the end of this time, is cooled to 0° and 3.5 g of cyanogen bromide dissolved in 10 ml of dry tetrahydrofuran is added dropwiese. The mixture is stirred at room temperature for 0.5 hour and evaporated under reduced pressure at 45°. The residue is 25 dissolved in methylene chloride, the solution is washed with water, dried over magnesium sulfate, decolorized with charcoal, and evaporated to a small volume. 5-Cyanomercapto-llH-imidazo[l,2-c]-[l,3]benzodiazepine, m.p. 111-113°, crystallized on dilution with ether.
2 027
Example 4: To a solution of 8.9 g of l-[2-(2-imidazolylmethyl)-phenylthiocarbamoyl]-4-ethoxycarbonylpiperazine in 70 ml of aceto-nitrile, cooled to 0°, is added 2.4 g of solid potassium carbonate while stirring, followed by dropwise addition of a solution of 2.5 g 5 of cyanogen bromide in 10 ml of acetonitrile; the mixture is allowed to warm up to room temperature overnight. The solids are filtered off, washed with ethyl acetate, and the filtrate is evaporated to dryness. The residue is dissolved in methylene chloride, the solution is washed with water, dried over magnesium sulfate, decolorized with 10 charcoal and evaporated to dryness. The residue is chromatographed with 250 g of silica gel using ethyl acetate-methanol (9:1) as eluant to give 5-(4-ethoxycarbonyl-l-piperazinyl)-llH-imidazo[l,2-c][1,3]-benzodiazepine, m.p. 137-139°.
The starting material is prepared as follows: A solution of 20 g 15 of 1-ethoxycarbonylpiperazine in 400 ml dry tetrahydrofuran is cooled to -65° and 61.5 ml of 2.1M solution of n-butyllithium in hexane is added dropwise over a period of 15 minutes. The mixture is stirred for 15 minutes and a solution of 16.44 ml of chlorotrimethyl-silane in 68 ml of tetrahydrofuran is added dropwise over a period 20 of 15 minutes. The mixture is then allowed to warm up to room temperature overnight and evaporated to dryness. Ethyl ether is added, the solids are filtered off, the filtrate is evaporated to dryness and the residue is distilled to give l-ethoxycarbonyl-4-trimethyl-silylpiperazine, b.p. 102-107°/0.1 mm Hg.
To a solution of 4.66 ml of 85% thiophosgene in 200 ml of ethyl ether, cooled to -76° is added, while stirring and under nitrogen, a solution of 7 g of l-ethoxycarbonyl-4-trimethylsilylpiperazine in 35 ml of ethyl ether over a period of 20 minutes. The mixture is allowed to warm up to room temperature overnight. The suspension is
2027
filtered and the filtrate is evaporated to dryness. The residue is crystallized from methylene chloride-hexane to give 4-ethoxycarbonyl-1-piperazinyl-thiocarbonyl chloride, m.p. 107-111°.
To a suspension of 3.8 g of 2-(2-aminobenzyl)-imidazole in 38 ml of 5 tetrahydrofuran and 3.23 ml of triethylamine is added dropwise a solution of 5.5 g 4-ethoxycarbonyl-l-piperazinyl-thiocarbonyl chloride in 10 ml of methylene chloride at room temperature. The mixture is stirred for 1 week and the suspension filtered. The filtrate is washed with first 10% aqueous potassium carbonate, then 10 with water, dried and evaporated to dryness to give amorphous 1—[2— (2-imidazolylmethyl)-phenylthiocarbamoyl]-4-ethoxycarbonylpiperazine, characterized by NMR,
Example 5: According to the methods illustrated by the previous examples, the following compounds of formula I, especially II wherein
R, and R„ represent hydrogen, and C H„ represents 1,2-ethylen were l ^ n 2n obtained from equivalent amounts of the corresponding starting materials.
No. R„ R. 3 4
l CH2CH2OH H
2 CH2CH20H CI
3 CH3 CI
4 CH3 H
ch3 h
Salt m.p.
143-4°
HC1 225° (decompo sition)
2HC1 226-8° (dec.)
2HC1 > 250° (dec.)
HC1 217-220°.
Example 6: The mixture of 315 mg of l-[2-(2-imidazolylmethyl)phenyl-25 thiocarbamoyl]-4-methylpiperazine, 3.3 ml of dimethylformamide,
276 mg of potassium carbonate, 116 mg of cyanogen bromide and 50 mg of 8-crown-6 ether is stirred at room temperature under nitrogen for 3 hours. It is diluted with ethyl acetate, washed with saturated
2027
aqueous sodium chloride, dried and evaporated. The residue is dissolved in acetone, the solution treated with 116 mg of maleic acid and diluted with diethyl ether, to yield 5-(4-methyl-l-piperazinyl)-HH-imidazo[1,2-c][l,3]benzodiazepine monomaleate. The product is 5 identical with that of Example 1.
The starting material is prepared as follows:
The mixture of 2.1 g of llH-imidazo[l,2-c][l,3]benzodiazepine-5(6H)~ thione, 23 ml of methylene chloride and 1.0 g of 1-methylpiperazine is stirred at room temperature for 15 hours. The crystalline product 10 formed is filtered off and washed with methylene chloride, to yield 1-[2-(2-imidazolylmethy1)-phenylthiocarbamoyl]-4-methylpiperazine.
Example 7: A mixture of 9.5 g of 5-methylthio-llH-imidazo[1,2-c][1,3]— benzodiazepine hydrochloride, 3.62 g of piperazine, and 350 ml of amyl alcohol is refluxed with stirring and under nitrogen for 15 20 hours. The solvent is evaporated under vacuum, the residue is triturated with methylene chloride, washed with 2N sodium hydroxide solution, dried over magnesium sulfate, and evaporated to dryness. The residue is dissolved in 10 ml of methanol and treated with 2N ethereal hydrochloric acid solution to give 5-(4H-l-piperazinyl)-llH-20 imidazofl,2-c][1,3]benzodiazepine dihydrochloride.
Examples 8: To a solution of 0.2 g of 5-(4-carboethoxy-l-piperazinyl-llH-imidazo[l,2-c][l,3]benzodiazepine in 2 ml of dry tetrahydrofuran, 100 mg of lithium aluminium hydride are added at once and the mixture is refluxed under nitrogen for 48 hours. The mixture is cooled 25 to room temperature, stirred with 0.2 ml of 30% aqueous sodium hydroxide, and filtered. The filtrates are evaporated to dryness and the product is purified to give 5-(4-methyl-l-piperazinyl]-HH-imidazo[1,2-c][l,3]benzodiazepine, which is identical with the product of example 1. It melts at 123-124°.
2 027
Example 9: To a solution of 82 mg of 5-(4-methyl-l-piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine in 1 ml of methylene chloride, 74 mg of m-chloroperbenzoic acid are added at 0°. The mixture is stirred at 0° overnight; this is diluted with 1 ml of ether, one equivalent of 5 ethereal hydrochloric acid solution is added and the resulting precipitate is collected. Recrystallization gives 5-(4-methyl-4-oxido-1-piperazinyl-llH-imidazo[1,2-c][1,3]benzodiazepine hydrochloride.
Example 10: To a solution of 100 mg of 5-(4-benzyloxycarbonyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine in 0.3 ml of 10 acetic acid are added 0.35 ml of a 2N solution of hydrobromic acid in acetic acid. The mixture is heated at 100° for 1 hour and stirred at room temperature overnight. Ether is added, and the 5-(4H-l-piperazin-yl)-llH-imidazo[1,2-c][l,3]benzodiazepine hydrobromide precipitates„
The starting material is prepared similarly to starting material of 15 exmaple 4 by replacing 1-ethoxycarbonylpiperazine with the equivalent amount of 1-benzyloxycarbonylpiperazine.
Example 11: A mixture of 265 mg of 5-(4H-l-piperazinyl)-llH-imidazo-[1,2-c][l,3]benzodiazepine 0.5 g of potassium carbonate, 0.142 g of methyl iodide and 2 ml of acetone is stirred at room temperature over-20 night and evaporated. Water is added to the residue, and the mixture is extracted with methylene chloride. The extracts are dried over magnesium sulfate, evaporated, and the residue is purified to give 5-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine.
Example 12: The following compounds of formula I (R,.-R^=H) are 25 prepared according to the methods illustrated by the previous examples and are obtained from equivalent amounts of the corresponding substituted starting materials.
2 027
No.
R1
R2
R3
R4
CnH2n
1
ch3
h
CH3
h
(CH2)2
2
CH3
CH3
ch3
h
(cV2
3
h h
CH3
8-cf3
(ch2)2
4
h h
ch3
8-f
(CH2)2
h h
ch3
8-0ch3
(ch2)2
6
h h
ch3
8-0h
(ch2)2
7
h h
ch3och2ch2
h
(CH2)2
8
h h
ch3c00ch2ch2
h
(ch2)2
9
h h
ch3
8-ch3
(ch2)2
Examples 13: Preparation of 10,000 tablets each containing 25 mg of the active ingredient:
Formula:
-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]-
benzodiazepine 250.00 g
Lactose 957.00 g Corn Starch 75.00 g Polyethylene glycol 6,000 75.00 g Talcum powder 75.00 g 20 Magnesium stearate 18.00 g Purified water q,s.
Procedure: All the powders are passes through a screen with openings of 0.6 mm. Then the drug substance, lactose, talcum, magnesium stearate and half of the starch are mixed in a suitable mixer. The 25 other half of the starch is suspended in 40 ml of water and the suspension added to the boiling solution of polyethylene glycol in 150 ml water. The paste formed is added to the powders which are granulated, if necessary, with an additional amount of water. The granulate is dried overnight at 35°, broken on a screen with 1.2 mm openings and 30 compressed into tablets using concave punches with 6.4 mm diameter, uppers bisected.
202714
Example 14: Preparation of 10,000 capsules each containing 50 mg of the active ingredient:
Procedure: All the powders are passed through a screen with openings of 0.6 mm. Then the drug substance is placed in a suitable mixer 10 and mixed first with the talcum, then with the lactose until homogenous. No. 34 capsules are filled with 200 mg, using a capsule filling machinec
Analogously tablets or capsules are prepared from the remaining compounds of the invention, e.g. those illustrated by the other 15 examples herein.
Example 15: A mixture of 10 g of l-[2-(4-methyl-2-imidazolylmethyl)-phenylcarbamoyl]-4-methylpiperazine, 86 ml of phosphorous oxychloride and 7.24 g of phosphorous pentachloride is stirred at room temperature for 4 hours and evaporated to dryness. The residue is suspended in 20 186 ml of methylene chloride and 55.2 ml of triethylamine is added dropwise at 0° over a period of 15 minutes. The mixture is stirred at room temperature overnight, poured into cold water, basified with 10% aqueous potassium carbonate and extracted with methylene chloride. The methylene chloride extracts are re-extracted with 2N aqueous 25 hydrochloric acid. The acidic extracts are basified with 2N aqueous sodium hydroxide and extracted three times with methylene chloride. The organic extracts are dried over magnesium sulfate, decolorized with charcoal and evaporated to dryness. The residue is chromato-
Formula:
-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]-
500.0 g
benzodiazepine monomaleate Lactose Talcum powder
1,400.0 g 100.0 g
2 027
graphed from 180 g of silica gel using methylene chloride-methanol-ammonium hydroxide (300:50:1) as eluant to give a foamy material which is dissolved in acetone and treated with an equivalent amount of maleic acid to give on dilution with ether the 2-methyl-5-(4-methyl-5 l-piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine mono-maleate, m.p. 195-197°.
The starting material is prepared as follows: A solution of ethanolic sodium ethoxide, prepared by desolving 4.48 g of sodium metal in 112 ml of absolute ethanol, is added dropwise to a suspension of 47.84 g of 10 ethyl 2-(2-nitrophenyl)-acetimidate hydrochloride in 224 ml of ethanol and the mixture is stirred at room temperature for one hour. The sodium chloride formed is filtered, 22.82 g of the ethylene ketal of 1-amino-2-propane is added to the filtrates and the mixture is stirred at room temperature overnight. The insoluble material is filtered off 15 and the filtrates are evaporated to dryness. The residue is dissolved in 470 ml of concentrated hydrochlorid acid and the solution is refluxed for 1 hour. The mixture is washed once with ether, basified with 2N sodium hydroxide and extracted three times with ethyl acetate. The extracts are dried over magnesium sulfate, decolorized with 20 charcoal and evaporated. The residue is crystallized from methylene chloride-ether to give 4-methyl-2-(2-nitrobenzyl)-imidazole, m.p. 125-128°.
A mixture of 23.44 g of 4-methyl-2-(2-nitrobenzyl)-imidazole, 2.34 g of 10% palladium on charcoal and 234 ml of ethanol is hydrogenated 25 at 42 psi (3 atmospheres) at room temperature for 4 hours. The catalyst is filtered and the filtrates are evaporated to dryness to give 4-methyl-2-(2-aminobenzyl)-imidadole showing signals in the NMR spectrum at & 2.09, 3.78, 6.08.
A mixture of 18.61 of 4-methyl-2-(2-aminobenzyl)-imidazole, 16.12 g 30 of 1,l'-carbonyldiimidazole and 375 ml of methylene chloride is stirred at room temperature overnight. The methylene chloride is
* ''' .
2027
evaporated to a small volume, the mixture is cooled to 0° and the solids are filtered and washed with ether to give 2-methyl-llH-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-one, m.p. 234.5-236.5°.
A mixture of 16 g of 2-methyl-llH-imidazo[1,2-c][l,3]benzodiazepine-5-5 (6H)-one, 9.58 g of N-methylpiperazine and 160 ml of methylene chloride is stirred at room temperature overnight. The mixture is decolorized with charcoal and evaporated to dryness. The residue is crystallized from methanol-ether to give l-[2-(4-methyl-2-imidazolylmethyl)-phenylcarbamoyl]-4-methylpiperazine, m.p. 177-179°.
Example 16: To a solution of 5 g of 5-(4-methyl-l-piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine in 50 ml of methylene chloride is added in portions 3.75 g of m-chloroperbenzoic acid with stirring at 0°. The mixture is then stirred at room temperature overnight and evaporated to dryness. The foamy residue is passed through 100 g of 15 Amberlite IRA-400 ion exchange resin using water as eluent. Evaporation of the eluent gives 5-(4-methyl-4-oxido-l-piperazinyl)-llH-imidazo[l,2-c][l,3]benzodiazepine as foamy material having Rf =
0.173 on silica gel plates using methylene chloride-methanol-ammonium hydroxide (150:50:1) as eluent, which is identical with product 20 obtained in Example 9.
Example 17: A mixture of 8.67 g of 5-methylthio-llH-imidazo[l,2-c]-[l,3]benzodiazepine, 3.38 g of piperazine and 326 ml of amyl alcohol is refluxed under nitrogen for 6 days and evaporated to dryness under reduced pressure. The residue is dissolved in methylene chloride 25 and the solution is washed successively with 10% aqueous potassium carbonate and brine, dried over magnesium sulfate, decolorized with charcoal and evaporated. The residue is chromatographed with 300 g of silica gel using methylene chloride-methanol-ammonium hydroxide (150:50:1) as eluent to give 5-(4H-l-piperazinyl)-llH-imidazo[l,2-c]-30 [l,3]benzodiazepine as an oil. The oil is treated with 2.74 g of maleic acid in acetone to give 5-(4H-l-piperazinyl)-llH-imidazo[l,2-c]-
Claims (25)
1. A compound of the general formula I R6\/7 R4 >\ / \ A ^ »-R (I) i " A 11 n1 X/\ /* 2;R * N_,\ ! X <"• n 2n wherein R^ and R^ independently represent hydrogen, lower alkyl, 5 lower alkanoyl, halogen, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, sulfamoyl, mono- or di-lower alkyl-(carbamoyl or sulfamoyl) ; CnH2n is lower alkylene separating both nitrogen atoms by 2 or 3 carbon atoms; R^ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, aryl lower alkyl, lower alkoxycarbonyl, 10 phenyl lower alkoxycarbonyl or (hydroxy, lower alkanoyloxy, aryloxy or lower alkoxy) lower alkyl having at least two carbon atoms; R^ and R,. independently represent hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, trifluoromethyl, hydroxy, lower alkanoyloxy, sulfamoyl, mono- or di-lower alkylsulfamoyl; and R and R_ o 7 15 independently represent hydrogen or lower alkyl; the N-oxides and lower alkyl quaternary derivatives thereof.
2. A compound of the formula I shown in claim 1, wherein R^ and R^ independently represent hydrogen, lower alkyl, cyano, carboxy, lower alkoxycarbonyl or carbamoyl; n represents the integer 2 or 3; is hydrogen, lower alkyl, lower alkoxycarbonyl, or hydroxy lower alkyl of 2 to 4 carbon atoms; represents hydrogen, lower 20 alkyl, lower alkoxy, lower alkylthio, halogen or trif luoromethyl ;R,_ represents hydrogen; and R, and R, independently represent hydrogen o / or lower alkyl; the N-oxides or lower alkyl quaternary derivatives thereof. ^ ^ r ' Ti.• 11 20ju^ s °'V C O ^ .• '• V 202714 - 38 -
3. A compound of the formula I shown in claim 1, wherein and R^ independently represent hydrogen, methyl, ethyl, cyano, carboxy, alkoxycarbonyl of 1 to 3 carbon atoms in the alkoxy portion or carbamoyl; n represents the integer 2 or 3; is hydrogen, alkyl of 5 1 to 3 carbon atoms, alkoxycarbonyl of 1 to 3 carbon atoms in the alkoxy portion, hydroxyethyl or hydroxypropyl; represents hydrogen, methyl, methoxy, methylthio, chloro or trifluoromethyl; R,_ represents hydrogen; R, and R independently represent hydrogen or methyl; the D / N-oxides or methyl quaternary derivatives thereof. 10
4. A compound of the formula II wherein R^ and R2 independently represent hydrogen or lower alkyl; R^ represents hydrogen, lower alkyl or hydroxy lower alkyl wherein the hydroxy group is separated from the nitrogen atom by at least 15 2 carbon atoms; R^ represents hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen or trifluoromethyl; C represents n 2 n ethylene or propylene; and the N-oxides thereof.
5. A compound of the formula II shown in claim 4, wherein R^ and R^ independently represent hydrogen or methyl; R^ represents hydrogen, 20 methyl, ethyl, propyl, 2-hydroxyethyl or 3-hydroxypropyl; R^ is hydrogen, methyl, methoxy, fluoro, chloro or trifluoromethyl; C represents ethylene or propylene; and the N-oxides thereof.
6. A compound of the formula II shown in claim 4, wherein R^ and R^ independently represent hydrogen or methyl; R^ represents hydrogen, 25 methyl, ethyl, propyl or 2-hydroxyethyl; R^ is hydrogen, methyl, ^ 20271A - 39 - fluoro, chloro or trifluoromethyl and C H- is ethylene. n 2n
7. 5-(4-Methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine.
8. 5-(4-Methyl-l-homo-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine. 5
9. 5-(4-Ethoxycarbonyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine.
10. 5-[4-(2-Hydroxyethyl)-l-piperazinyl)-llH-imidazo[l,2-c][1,3]benzodiazepine.
11. 8-Chloro-5-[4-(2-hydroxyethyl)-1-piperazinyl]-llH-imidazo-[1,2-c][l,3]benzodiazepine.
12. 8-Chloro-5-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]— benzodiazepine.
13. 2-Methyl-5-(4-methyl-l-piperazinyl)-llH-imidazo[1,2-c][1,3]benzodiazepine . 15
14. 5-(4H-l-piperazinyl)-llH-imidazo[l,2-c][1,3]benzodiazepine.
15. A salt of a compound having a salt forming group, as claimed in any one of claims 1 to 12.
16. A pharmaceutically acceptable salt of a compound having a salt forming group, as claimed in any one of claims 1 to 12. 20
17. A salt of a compound having a salt forming group, as claimed in either of claims 13 and 14. " 202714 - 40 -
18. A pharmaceutically acceptable salt of a compound having a salt forming group, as claimed in either of claims 13 and 14.
19. A pharmaceutical preparation comprising a compound claimed in any one of claims 1 to 12 and 16 in admixture or conjunction with 5 a pharmaceutically suitable carrier.
20. A pharmaceutical preparation comprising a compound claimed in any one of claims 13, 14 and 18 in admixture or conjunction with a pharmaceutically suitable carrier.
21. A process for the manufacture of a compound of formula I 10 claimed in claim 1, of the N-oxides, lower alkyl quaternary derivatives, and salts thereof, which consists in a) condensing a compound of formula III wherein X is a group able to be removed with hydrogen or an alkali 15 metal and the remaining symbols have meanings as defined for formula I; with a compound of formula IV (III) (IV) or an alkali metal derivative thereof wherein and n have meanings as defined for formula I; or 20 b) cyclizing a compound of formula VI 20 NOV ft - 41 - 202714 R, > \/ ° -R, HN—•-R„ -c-n( ii v -R„ n 2n (vi) wherein Z is oxygen, sulfur, or NH, and the other symbols have the meanings as defined for formula I, under dehydrating, dehydrosulfu-rating or deamination conditions, and/or 5 1) if a compound of the formula I is required in which R^ is lower alkyl, introducing such a radical into a compound of the formula I in which R^ is hydrogen or an alkali metal atom, and/or 2) if a compound is required in which R^ is lower alkyl, reducing a compound having a lower alkenyl or lower alkynyl group instead of 10 a lower alkyl group, and/or 3) if a compound is required in which R^ is hydroxy-lower alkyl, reacting a compound in which R^ is hydrogen or an alkali metal atom with a corresponding oxirane or with a reactive ester of a mono-esterified lower alkanediol, and/or, 15 4) if a compound is required in which R^ is hydroxy-lower alkyl, reacting a compound in which R^ is hydrogen with a reactive derivative of a corresponding glycol, glycolic acid or a dicarboxylic acid and hydrolyzing or reducing the compound so obtained to a compound in which R^ is hydroxy-lower alkyl, and/or, 20 5) if a compound is required in which R^ is lower alkoxycarbonyl, converting a compound in which R^ is lower alkyl into a lower alkoxycarbonyl group, and/or, r/V [N 6) if a compound is required in which R^ is an acyl radical named above, acylating a compound in which R^ is hydrogen, and/or 202714 - 42 - 7) if a compound is required in which represents hydrogen, hydrolyzing a compound in which R^ is an acyl radical, and/or, 8) if a compound is required in which R^ represents methyl, reducing a compound in which R^ is lower alkoxycarbonyl or phenyl-lower alkoxycarbonyl to obtain a compound in which R^ is methyl, and/or, 9) if a compound is required in which R^ and/or R2 is/are halogen, halogenating a compound in which R^ and/or R^ is/are hydrogen, and/or, 10) if a compound is required in which R^ and/or R^ is/are carboxy, lower alkoxycarbonyl or a carbamoyl residue named above, reacting a compound in which R^ and/or R^ is/are hydrogen, with a trihaloacetyl halide and treating the compound obtained with an alkali metal lower alkoxide, alkali metal hydroxide or alkali metal amide, and/or, 11) if a compound is required in which R^ and/or R^ is/are sulfamoyl, mono- or di-lower alkylsulfamoyl, reacting a compound in which R^ and/ or R2 is/are hydrogen with a halosulfonic acid and treating the compound obtained with ammonia, a mono- or di-lower alkylamino, and/or, 12) if a compound is required in which R^ and/or R^ is/are cyano, dehydrating a compound in which R^ and/or R^ is/are carbamoyl, and/or, 13) if a compound is required in which R^ and/or R^ is/are carboxy, hydrolyzing a compound in which R^ and/or R^ is/are cyano, lower alkoxycarbonyl or carbamoyl, and/or, 14) if an N-oxide is required, oxidizing a compound in which is different from hydrogen, and/or, 15) if a lower alkyl quaternary derivative is required, reacting a compound in which represents hydrogen or alkali metal with a reactive esterified lower alkanol, and/or, 202714 - 43 - 16) if required, converting a resulting compound of formula I into another compound of the invention, and/or, if required, converting a resulting free compound into a salt or a resulting salt into the free compound or into another salt, and/or, if required, resolving 5 a mixture of isomers or racemates obtained into the single isomers or racemates, and/or, if required, resolving a recemate obtained into the optical antipodes.
22. The process for the preparation of a compound as defined in claim 1 described in any one of examples 1 to 12. 10
23. The process for the preparation of a compound as defined in claim 1 described in any one of examples 15 to 19.
24. The compounds prepared according to claim 22.
25. The compounds prepared according to either of c 3^23.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32827481A | 1981-12-07 | 1981-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ202714A true NZ202714A (en) | 1986-08-08 |
Family
ID=23280276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ202714A NZ202714A (en) | 1981-12-07 | 1982-12-06 | 5-diazacycloalkyl-imidazo(1,2-c)(1,3)benzodiazepine derivatives,a method for their preparation and pharmaceutical preparations |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0081461A3 (en) |
JP (1) | JPS58109489A (en) |
AU (1) | AU9131582A (en) |
CA (1) | CA1180011A (en) |
DD (1) | DD203547A5 (en) |
DK (1) | DK540282A (en) |
ES (2) | ES517912A0 (en) |
FI (1) | FI824170L (en) |
GB (1) | GB2115407B (en) |
GR (1) | GR77796B (en) |
HU (1) | HU187191B (en) |
IL (1) | IL67426A0 (en) |
NO (1) | NO824090L (en) |
NZ (1) | NZ202714A (en) |
PT (1) | PT75940B (en) |
ZA (1) | ZA828954B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595535A (en) * | 1983-06-06 | 1986-06-17 | Ciba-Geigy Corporation | Diazacycloalkyl-1,2,4-triazolo[2,3-c][1,3]benzodiazepines useful as neuroleptic and/or antihistaminic agents |
EP0129509B1 (en) * | 1983-06-06 | 1989-08-23 | Ciba-Geigy Ag | Triazolo (2,3-c)(1,3)benzodiazepines, process for their preparation, pharmaceutical compositions containing them and their therapeutical use |
KR102122470B1 (en) | 2016-12-08 | 2020-06-12 | 주식회사 엘지화학 | Modified agent and modified conjugated diene polymer comprising functional group derived from the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838122A (en) * | 1972-06-30 | 1974-09-24 | J Suh | 2-heterocyclic-1,3-benzodiazepines |
JPS57118589A (en) * | 1980-06-12 | 1982-07-23 | Ciba Geigy Ag | Imidazobenzothiazepine, manufacture, pharmaceutical medicine containing same and use as medicine |
-
1982
- 1982-11-03 FI FI824170A patent/FI824170L/en not_active Application Discontinuation
- 1982-12-01 EP EP82810516A patent/EP0081461A3/en not_active Ceased
- 1982-12-02 GB GB08234334A patent/GB2115407B/en not_active Expired
- 1982-12-03 ES ES517912A patent/ES517912A0/en active Granted
- 1982-12-03 CA CA000416953A patent/CA1180011A/en not_active Expired
- 1982-12-06 PT PT75940A patent/PT75940B/en unknown
- 1982-12-06 IL IL67426A patent/IL67426A0/en unknown
- 1982-12-06 DD DD82245615A patent/DD203547A5/en unknown
- 1982-12-06 NO NO82824090A patent/NO824090L/en unknown
- 1982-12-06 GR GR69999A patent/GR77796B/el unknown
- 1982-12-06 AU AU91315/82A patent/AU9131582A/en not_active Abandoned
- 1982-12-06 HU HU823911A patent/HU187191B/en unknown
- 1982-12-06 ZA ZA828954A patent/ZA828954B/en unknown
- 1982-12-06 NZ NZ202714A patent/NZ202714A/en unknown
- 1982-12-06 DK DK540282A patent/DK540282A/en not_active Application Discontinuation
- 1982-12-06 JP JP57212828A patent/JPS58109489A/en active Pending
-
1984
- 1984-02-28 ES ES530125A patent/ES530125A0/en active Granted
Also Published As
Publication number | Publication date |
---|---|
DK540282A (en) | 1983-06-08 |
NO824090L (en) | 1983-06-08 |
PT75940A (en) | 1983-01-01 |
PT75940B (en) | 1985-12-20 |
ES8601189A1 (en) | 1985-11-01 |
FI824170A0 (en) | 1982-11-03 |
FI824170L (en) | 1983-06-08 |
HU187191B (en) | 1985-11-28 |
GB2115407B (en) | 1985-07-24 |
ES8501757A1 (en) | 1984-12-01 |
AU9131582A (en) | 1983-06-16 |
ZA828954B (en) | 1983-09-28 |
CA1180011A (en) | 1984-12-27 |
ES517912A0 (en) | 1984-12-01 |
DD203547A5 (en) | 1983-10-26 |
EP0081461A3 (en) | 1984-07-18 |
ES530125A0 (en) | 1985-11-01 |
IL67426A0 (en) | 1983-05-15 |
EP0081461A2 (en) | 1983-06-15 |
GB2115407A (en) | 1983-09-07 |
GR77796B (en) | 1984-09-25 |
JPS58109489A (en) | 1983-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1150253A (en) | Dibenzoimidazoazepines, -oxazepines and -thiazepines and pharmaceutical compositions containing them | |
CZ17094A3 (en) | BENZIMIDAZOLE DERIVATIVES AS 5-HT1a AND 5-HT2 ANTAGONISTS | |
EP0070171A1 (en) | Novel piperidine derivatives, processes for preparation thereof and pharmaceutical compositions containing same | |
US4179503A (en) | 1-Hydroxyalkanamine pyrano[3,4-b]indole derivatives | |
CA1109064A (en) | New, in 11-position substituted, 5,11-dihydro-6h- pyrido [2,3-b] - [1,4] benzodiazepine-6-ones, processes for their production and pharmaceutical compositions containing them | |
US3983239A (en) | Hexahydro-γ-carboline derivatives and their salts | |
US4444688A (en) | Imidazobenzothiadiazepines | |
EP0414422A2 (en) | 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | |
US4089960A (en) | Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides | |
US4889856A (en) | 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers | |
US4460587A (en) | 5-Diazacycloalkyl imidazo[1,2-c][1,3]benzodiazepines | |
US4492699A (en) | Triazolobenzodiazepine derivatives | |
CA1180011A (en) | Imidazobenzodiazepines | |
US4309348A (en) | Tricyclic indole derivatives | |
US4507311A (en) | Imidazo[1,2-c][1,3]benzodiazepines | |
FR2558835A1 (en) | HYDANTINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICAMENT CONTAINING SAME | |
US4460508A (en) | 5-Diazacycloalkylimidazo[1,2-c][1,3]benzodiazepines | |
US4459232A (en) | Imidazo[1,2-c][1,3]benzodiazepines | |
US5071849A (en) | Dihydropyrimidothiazine derivatives | |
PL116688B1 (en) | Process for the preparation of trinuclear compounds with nitrogen atom in nodal position | |
US5077295A (en) | Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides | |
NO754001L (en) | ||
US4391808A (en) | 5(1-Piperazinyl(imidazo[2,1-b][1,3,5]benzothiadiazepines | |
US4595535A (en) | Diazacycloalkyl-1,2,4-triazolo[2,3-c][1,3]benzodiazepines useful as neuroleptic and/or antihistaminic agents | |
US4209514A (en) | 3-Aminoalkyl-4-aryl-tetrahydroazepines |